Caris Life Sciences (NASDAQ:CAI) Earns Buy Rating from Analysts at The Goldman Sachs Group

The Goldman Sachs Group began coverage on shares of Caris Life Sciences (NASDAQ:CAI) in a research note released on Wednesday, Marketbeat reports. The firm issued a buy rating and a $27.00 price objective on the stock.

Several other research analysts also recently commented on CAI. BTIG Research cut their target price on Caris Life Sciences from $45.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, February 27th. Weiss Ratings reissued a “sell (d)” rating on shares of Caris Life Sciences in a report on Monday, December 29th. Evercore set a $38.00 price objective on shares of Caris Life Sciences in a research report on Monday, January 5th. Robert W. Baird boosted their price objective on shares of Caris Life Sciences from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, February 27th. Finally, Wall Street Zen upgraded shares of Caris Life Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Caris Life Sciences presently has an average rating of “Hold” and a consensus price target of $30.60.

Caris Life Sciences Price Performance

Shares of Caris Life Sciences stock opened at $19.29 on Wednesday. The stock has a market cap of $5.45 billion and a price-to-earnings ratio of -107.17. Caris Life Sciences has a 1 year low of $16.28 and a 1 year high of $42.50. The company has a current ratio of 7.85, a quick ratio of 7.35 and a debt-to-equity ratio of 0.66. The company’s fifty day simple moving average is $20.19.

Caris Life Sciences (NASDAQ:CAI) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.27. The company had revenue of $292.89 million during the quarter, compared to the consensus estimate of $281.00 million. During the same period last year, the firm posted ($1.73) EPS. The company’s revenue for the quarter was up 125.4% compared to the same quarter last year.

Institutional Trading of Caris Life Sciences

A number of institutional investors have recently made changes to their positions in CAI. Global Retirement Partners LLC lifted its holdings in Caris Life Sciences by 99,900.0% in the 4th quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock worth $27,000 after buying an additional 999 shares during the period. Olistico Wealth LLC bought a new position in shares of Caris Life Sciences during the fourth quarter valued at approximately $31,000. MetLife Investment Management LLC lifted its stake in Caris Life Sciences by 84.0% in the fourth quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock worth $45,000 after acquiring an additional 755 shares during the period. Aster Capital Management DIFC Ltd bought a new stake in Caris Life Sciences in the fourth quarter valued at $67,000. Finally, Federated Hermes Inc. purchased a new position in Caris Life Sciences during the 4th quarter valued at $81,000.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.